Chemical Biology & Drug Design · 2020 · 19 citations · 25 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryStructure-activity RelationshipsVirologyAntiviral AgentsAntiviral PharmacologyLead Compound DesignLigand BindingNatural Product Drug DiscoveryStructure-activity Relationship AnalysisAntiviral Drug DesignAntiviral Drug MechanismsAntiviral Structure-activity RelationshipsAntiviral TherapeuticsLead Compound IdentificationLead Compound Screening
Abstract Methyl brevifolincarboxylate (MBC) was isolated from ethyl acetate extract of Canarium album (Lour.) Raeusch. The structure was identified, and the effect on influenza A virus infection was evaluated. MBC exhibited inhibitory activity against influenza virus A/Puerto Rico/8/34 (H1N1) and A/Aichi/2/68 (H3N2) with IC 50 values of 27.16 ± 1.39 μM and 33.41 ± 2.34 μM. Mechanism studies indicated that MBC inhibited the replication of influenza A virus by targeting PB2 cap‐binding domain. Our results demonstrated MBC was a potent PB2 cap‐binding inhibitor and represented as a new type of promising lead compound for the development of anti‐influenza virus drugs from natural products.
25
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
Frederick G. Hayden, Norio Sugaya, Nobuo Hirotsu et al. · New England Journal of Medicine · 2018 · 929 citations · Full text
Mechanism of Action of T-705 against Influenza Virus
Yousuke Furuta, Kazumi Takahashi, Masako Kuno-Maekawa et al. · Antimicrobial Agents and Chemotherapy · 2005 · 548 citations · Full text
New low-viscosity overlay medium for viral plaque assays.
Mikhail Matrosovich, Tatyana Matrosovich, Wolfgang Garten et al. · Virology Journal · 2006 · 495 citations · Full text
Structural insight into cap-snatching and RNA synthesis by influenza polymerase
Stefan Reich, Delphine Guilligay, A. Pflug et al. · Nature · 2014 · 464 citations